MONOCLONAL ANTIBODIES IN NEPHROLOGY

Abstract Monoclonal antibodies have revolutionized renal medicine by enabling targeted modulation of immune pathways involved in glomerular, vascular, and transplant-related kidney diseases. Unlike conventional immunosuppressants, monoclonal antibodies bind specific antigens with high affinity, improving efficacy while reducing off-target toxicity. Their impact has been particularly significant in autoimmune glomerulopathies, complement-mediated disorders, and antibody-mediated transplant rejection. Many renal diseases are immune-mediated, involving B-cell dysregulation, autoantibody production, immune complex deposition, complement activation, and inflammatory cytokines. Rituximab, an anti-CD20 monoclonal antibody, depletes B cells through complement-dependent and antibody-dependent cytotoxicity. It has shown strong efficacy in membranous nephropathy and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, and although early trials in lupus nephritis were inconclusive, it remains useful in selected or refractory cases. Second-generation anti-CD20 agents, such as obinutuzumab, demonstrate enhanced cytotoxicity and promising results in lupus nephritis. Complement inhibition represents another major advance. Eculizumab, a C5 inhibitor, has dramatically improved outcomes in atypical hemolytic uremic syndrome, while ravulizumab offers extended dosing with similar efficacy. Complement blockade is also being explored in C3 glomerulopathy and transplant rejection. Emerging therapies include iptacopan, targeting factor B of the alternative pathway, and sutimlimab, inhibiting C1s in the classical pathway. Other strategies include interleukin-6 receptor blockade with tocilizumab and B-cell activating factor (BAFF) inhibition with belimumab in lupus nephritis. Despite clear benefits, monoclonal antibodies carry infection risks, infusion reactions, and high costs. Overall, they represent a cornerstone of precision-based nephrology, with ongoing research refining patient selection and long-term outcomes.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-02-28
DOI
https://doi.org/10.5281/zenodo.19177701
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MONOCLONAL ANTIBODIES IN NEPHROLOGY

Valera Gasparoto André Luis, Rocha Martinez Tania Leme da, Pantoja Margeotto Ana Paula, L R Saldanha Anita
Zenodo (CERN European Organization for Nuclear Research)
Complement system in diseases
article

MONOCLONAL ANTIBODIES IN NEPHROLOGY

Valera Gasparoto André Luis, Rocha Martinez Tania Leme da, Pantoja Margeotto Ana Paula, L R Saldanha Anita
article en

Abstract

Abstract Monoclonal antibodies have revolutionized renal medicine by enabling targeted modulation of immune pathways involved in glomerular, vascular, and transplant-related kidney diseases. Unlike conventional immunosuppressants, monoclonal antibodies bind specific antigens with high affinity, improving efficacy while reducing off-target toxicity. Their impact has been particularly significant in autoimmune glomerulopathies, complement-mediated disorders, and antibody-mediated transplant rejection. Many renal diseases are immune-mediated, involving B-cell dysregulation, autoantibody production, immune complex deposition, complement activation, and inflammatory cytokines. Rituximab, an anti-CD20 monoclonal antibody, depletes B cells through complement-dependent and antibody-dependent cytotoxicity. It has shown strong efficacy in membranous nephropathy and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, and although early trials in lupus nephritis were inconclusive, it remains useful in selected or refractory cases. Second-generation anti-CD20 agents, such as obinutuzumab, demonstrate enhanced cytotoxicity and promising results in lupus nephritis. Complement inhibition represents another major advance. Eculizumab, a C5 inhibitor, has dramatically improved outcomes in atypical hemolytic uremic syndrome, while ravulizumab offers extended dosing with similar efficacy. Complement blockade is also being explored in C3 glomerulopathy and transplant rejection. Emerging therapies include iptacopan, targeting factor B of the alternative pathway, and sutimlimab, inhibiting C1s in the classical pathway. Other strategies include interleukin-6 receptor blockade with tocilizumab and B-cell activating factor (BAFF) inhibition with belimumab in lupus nephritis. Despite clear benefits, monoclonal antibodies carry infection risks, infusion reactions, and high costs. Overall, they represent a cornerstone of precision-based nephrology, with ongoing research refining patient selection and long-term outcomes.

Zenodo (CERN European Organization for Nuclear Research)
Beneficência Portuguesa de São Paulo (BR)
Good health and well-being
Openalex Percentile: Top 11%
Complement system in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

MONOCLONAL ANTIBODIES IN NEPHROLOGY — Valera Gasparoto André Luis, Rocha Martinez Tania Leme da, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS